Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia

There has been an increase usage of anticoagulant among atrial fibrillation worldwide. Warfarin remains one of the commonest anticoagulant use. Prior to starting treatment, bleeding risk need to be assess in order to minimize patients’ risk of bleeding. HASBLED is a simple and user friendly to us...

Full description

Bibliographic Details
Main Author: Idris, Sri Salwani
Format: Thesis
Language:English
Published: 2018
Subjects:
Online Access:http://eprints.usm.my/48555/1/Dr.%20Sri%20Salwani%20Idris-24%20pages.pdf
_version_ 1797011999345868800
author Idris, Sri Salwani
author_facet Idris, Sri Salwani
author_sort Idris, Sri Salwani
collection USM
description There has been an increase usage of anticoagulant among atrial fibrillation worldwide. Warfarin remains one of the commonest anticoagulant use. Prior to starting treatment, bleeding risk need to be assess in order to minimize patients’ risk of bleeding. HASBLED is a simple and user friendly to use. Unfortunately, the utilization and usage of HAS-BLED prior to starting anticoagulant in HUSM was not known and not yet being studied. This study had been done to assess utilization of HAS-BLED and its impact on the occurrence of gastrointestinal bleeding (GIB). This retrospective study was performed among atrial fibrillation (AF) patients who attended INR or KRK outpatient clinic between January 2011 to December 2017. 88 patients were eligible for this study and their HAS-BLED were assess. Patients above 18 years old with AF who received warfarin were included in this study. Exclusion criteria include those who were taking warfarin for other causes than atrial fibrillation. We aimed to determine the rate of GIB among AF patients who are on warfarin, assess GIB risk using HAS-BLED and determine the association between GIB in AF patients with and without HAS-BLED. Among the selected 88 patients, the incidence rate of GIB is 5.7 cases per 100 patientyears. 44 (50%) had HAS-BLED assessment done prior to starting anticoagulant. The mean age of those who received warfarin was 64 years old with gender equally distributed. 83 (94.1%) patients who were started on warfarin had CHA2DS2 VASc score ≥2. GIB occurred in 11 (12.5%) out of 88 patients. Six (13.6%) patients were with HASBLED and 5 (11.4%) belong to the high risk group. The mean score for 44 patients with HAS-BLED was 1.92 (±0.936) and the mean score for 6 patients with GIB was much higher that was 2.83 (±0.98). The bleeding rate for every 100 patient-years was 0.53 and 2.63 for HAS-BLED score of 1 and 3 respectively. There was no association between GIB and HAS-BLED (p value= 0.747). There was association between GIB and duration of warfarin intake less than 30 days (p value <0.005). In conclusion, the utilisation of HAS-BLED remains low. There is no association between HAS-BLED and GIB. However, HAS-BLED is important to determine modifiable risk factors prior to starting warfarin to reduce GIB.
first_indexed 2024-03-06T15:42:13Z
format Thesis
id usm.eprints-48555
institution Universiti Sains Malaysia
language English
last_indexed 2024-03-06T15:42:13Z
publishDate 2018
record_format dspace
spelling usm.eprints-485552021-03-08T08:43:14Z http://eprints.usm.my/48555/ Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia Idris, Sri Salwani RC666-701 Diseases of the circulatory (Cardiovascular) system There has been an increase usage of anticoagulant among atrial fibrillation worldwide. Warfarin remains one of the commonest anticoagulant use. Prior to starting treatment, bleeding risk need to be assess in order to minimize patients’ risk of bleeding. HASBLED is a simple and user friendly to use. Unfortunately, the utilization and usage of HAS-BLED prior to starting anticoagulant in HUSM was not known and not yet being studied. This study had been done to assess utilization of HAS-BLED and its impact on the occurrence of gastrointestinal bleeding (GIB). This retrospective study was performed among atrial fibrillation (AF) patients who attended INR or KRK outpatient clinic between January 2011 to December 2017. 88 patients were eligible for this study and their HAS-BLED were assess. Patients above 18 years old with AF who received warfarin were included in this study. Exclusion criteria include those who were taking warfarin for other causes than atrial fibrillation. We aimed to determine the rate of GIB among AF patients who are on warfarin, assess GIB risk using HAS-BLED and determine the association between GIB in AF patients with and without HAS-BLED. Among the selected 88 patients, the incidence rate of GIB is 5.7 cases per 100 patientyears. 44 (50%) had HAS-BLED assessment done prior to starting anticoagulant. The mean age of those who received warfarin was 64 years old with gender equally distributed. 83 (94.1%) patients who were started on warfarin had CHA2DS2 VASc score ≥2. GIB occurred in 11 (12.5%) out of 88 patients. Six (13.6%) patients were with HASBLED and 5 (11.4%) belong to the high risk group. The mean score for 44 patients with HAS-BLED was 1.92 (±0.936) and the mean score for 6 patients with GIB was much higher that was 2.83 (±0.98). The bleeding rate for every 100 patient-years was 0.53 and 2.63 for HAS-BLED score of 1 and 3 respectively. There was no association between GIB and HAS-BLED (p value= 0.747). There was association between GIB and duration of warfarin intake less than 30 days (p value <0.005). In conclusion, the utilisation of HAS-BLED remains low. There is no association between HAS-BLED and GIB. However, HAS-BLED is important to determine modifiable risk factors prior to starting warfarin to reduce GIB. 2018 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/48555/1/Dr.%20Sri%20Salwani%20Idris-24%20pages.pdf Idris, Sri Salwani (2018) Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia. Masters thesis, Universiti Sains Malaysia.
spellingShingle RC666-701 Diseases of the circulatory (Cardiovascular) system
Idris, Sri Salwani
Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia
title Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia
title_full Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia
title_fullStr Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia
title_full_unstemmed Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia
title_short Gastrointestinal bleeding risk assessment using HAS-Bled in atrial fibrillation patients who are receiving warfarin in Hospital Universiti Sains Malaysia
title_sort gastrointestinal bleeding risk assessment using has bled in atrial fibrillation patients who are receiving warfarin in hospital universiti sains malaysia
topic RC666-701 Diseases of the circulatory (Cardiovascular) system
url http://eprints.usm.my/48555/1/Dr.%20Sri%20Salwani%20Idris-24%20pages.pdf
work_keys_str_mv AT idrissrisalwani gastrointestinalbleedingriskassessmentusinghasbledinatrialfibrillationpatientswhoarereceivingwarfarininhospitaluniversitisainsmalaysia